Habituation-induced neural plasticity in the hippocampus and prefrontal cortex mediated by MMP-3.
Head-shake response (HSR) habituation was presently used to investigate the phenomena of spontaneous recovery and neural plasticity. Independent groups of rats were presented with five consecutive habituation sessions separated by inter-session intervals (ISIs) of 2, 24 or 72 h. At the conclusion of testing hippocampus and prefrontal cortex tissue samples were collected for determination of matrix metalloproteinase-3 (MMP-3:stromelysin-1) expression as a marker of neural plasticity. The results indicated that by the fifth session the 2 h ISI group showed no spontaneous recovery, the 72 h ISI group revealed nearly complete spontaneous recovery; while the 24 h ISI group showed intermediate recovery. MMP-3 expression in the hippocampus and prefrontal cortex was elevated in the 2 and 72 h ISI groups, but not in the 24 h group. A second experiment utilized 7-day osmotic pumps to intracerebroventricularly infuse an MMP-3 inhibitor for 6 days. The animals were then tested on the seventh day using the 2 h ISI protocol. Delivery of the MMP-3 inhibitor facilitated spontaneous recovery, thus compromising the animal's ability to appropriately habituate. This effect was accompanied by a significant inhibition of hippocampus and prefrontal cortex MMP-3 expression. These results suggest that elevations in hippocampus and prefrontal cortex MMP-3 expression contribute to this simplest form of learning and may be a mechanism underlying spontaneous recovery.
Wright
John W
JW
Department of Psychology, Washington State University, Pullman, WA 99164-4820, United States. wrightjw@wsu.edu
Meighan
Peter C
PC
Brown
Travis E
TE
Wiediger
Roberta V
RV
Sorg
Barbara A
BA
Harding
Joseph W
JW
D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006185:Habituation, Psychophysiologic / Q000187:drug effects / Q000502:physiology*; D006257:Head; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology*; D007858:Learning / Q000187:drug effects / Q000502:physiology; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D053505:Matrix Metalloproteinases, Secreted / Q000037:antagonists & inhibitors; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology*; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D053505:Matrix Metalloproteinases, Secreted; D019278:Matrix Metalloproteinase 3